From Flexion Snags Pfizer Bucks, Three Pharma Deals, For New Drug Model:

clayman

clayman—

Mike Clayman is CEO of Flexion Therapeutics.

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
Bridging the Diversity Gap with Decentralized Trials
How a patient-centric, technology-driven approach can broaden access to research and reach patients regardless of geography, ethnicity, sex, or gender
PRA Health Sciences

From Our Editors · Podcast
Xcelerating Life Sciences Philadelphia: The Highlights Podcast
Becoming the Cell & Gene Therapy Hub

Sponsored · Video
Fish & Richardson: Patent Law in Regards to AI and Machine Learning
A Fireside Chat with Fish & Richardson Principal Teresa Lavoie
Fish & Richardson

Xconomy on Demand

We offer a number of ways to subscribe for free!